Page 105 - Demo

Cannabidiol for severe behavioral manifestations in TSC, MPS III, and FXS103443. Müller AR, Zinkstok JR, Rommelse NNJ, van de Ven PM, Roes KCB, Wijburg FA, et al. Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials. Orphanet J Rare Dis. 2021;16(1). 44. Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al. The Power of 1: Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology. 2021.45. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7). 46. Senn S. Sample size considerations for n-of-1 trials. Stat Methods Med Res. 2019.47. Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic. 1985.48. Müller AR, Luijten MAJ, Haverman L, De Ranitz-Greven WL, Janssens P, Rietman AB, et al. Understanding the impact of Tuberous Sclerosis Complex: Development and validation of the TSC-PROM. Press. 2023.49. Shapiro EG, Escolar ML, Delaney KA, Mitchell JJ. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses. Molecular Genetics and Metabolism. 2017. 50. Varni JW, Seid M, Rode CA. The PedsQLTM: Measurement model for the pediatric quality of life inventory. Med Care. 1999;37(2). 51. Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. Reliability and Validity of an Assessment Instrument for Anxiety, Depression, and Mood among Individuals with Mental Retardation. Journal of Autism and Developmental Disorders. 2003. 52. Rutter Bailey, A., & Lord, C. M. Manual of the Social Communication Questionnaire. Los Angeles, CA. 2003; 53. Constantino CPG& JN. Social Responsiveness Scale ( SRS ). Los Angeles, CA West Psychol Serv. 2011;(2005). 54. McIntosh DN, Miller LJ, Shyu V, Dunn W. Development and validation of the short sensory profile. Sens profile Man. 1999;61:59–73. 55. Vermulst A, Kroes G, de Meyer R, Nguyen L, Veerman JW. Opvoedingsbelastingvragenlijst ( OBVL ). Praktikon. 2012.56. Gaasterland CMW, Van Der Weide MCJ, Roes KCB, Van Der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: A conceptual proposal for validation. BMC Med Res Methodol. 2019.57. Elliott R, Wagner J, Sales CMD, Rodgers B, Alves P, Café MJ. Psychometrics of the personal questionnaire: A client-generated outcome measure. Psychol Assess. 2016.58. Sparrow SS, Cicchetti D V., Saulnier CA. Vineland Adaptive Behavior Scales, Third Edition. San Antonio, TX: Pearson; 2016. 59. Pepperdine CR, McCrimmon AW. Test Revie Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). Can J Sch Psychol. 2018;33(2). 60. Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism. 2015.61. Schmidt JD, Huete JM, Fodstad JC, Chin MD, Kurtz PF. An evaluation of the Aberrant Behavior Checklist for children under age 5. Res Dev Disabil. 2013.62. Stoddard J, Zik J, Mazefsky CA, DeChant B, Gabriels R. The Internal Structure of the Aberrant Behavior Checklist Irritability Subscale: Implications for Studies of Irritability in TreatmentSeeking Youth With Autism Spectrum Disorders. Behav Ther. 2020;51(2). 63. Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial. Pediatr Drugs. 2013;15(6). 64. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012.Annelieke Muller sHL.indd 103 14-11-2023 09:07